AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7851108 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment S
Number of subjects: 0
Study 3132551 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.10 mg/kg)
Number of subjects: 6
Study 3132551 — intervention group
Group type: EXPERIMENTAL
Intervention: Flumazenil (0.20 mg/kg)
Number of subjects: 6
Study 3132551 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 29580209 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb muscle strength
Number of subjects: 114
Study 29580209 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of steps taken per day
Number of subjects: 114
Study 29580209 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper limb muscle strength (assistive device users)
Number of subjects: 114
Study 29580209 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb muscle strength (non-assistive device users)
Number of subjects: 114
Study 29580209 — intervention group
Group type: EXPERIMENTAL
Intervention: Time spent in light physical activity (non-assistive device users)
Number of subjects: 114
Study 29580209 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of steps walked per day (non-assistive device users)
Number of subjects: 114
Study 28235809 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation in patients with plaque rupture (n=79)
Number of subjects: 141
Study 28235809 — intervention group
Group type: COMPARATOR
Intervention: Stent implantation in patients with plaque erosion (n=62)
Number of subjects: 141
Study 28235809 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-stent OCT findings in plaque rupture group
Number of subjects: 141
Study 28235809 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac event rates at 1-year follow-up for plaque rupture and erosion groups
Number of subjects: 141
Study 25640664 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone (50 mg for 10 days)
Number of subjects: 55
Study 23469944 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 128
Study 21497629 — intervention group
Group type: EXPERIMENTAL
Intervention: DTPa
Number of subjects: 53
Study 21497629 — intervention group
Group type: COMPARATOR
Intervention: dTpa
Number of subjects: 53
Study 21497629 — intervention group
Group type: EXPERIMENTAL
Intervention: Both DTPa and dTpa
Number of subjects: 53
Study 19968391 — intervention group
Group type: EXPERIMENTAL
Intervention: Best practice treatment conditions
Number of subjects: 0
Study 19968391 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 0
Study 16518760 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ) plus sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2084
Study 16518760 — intervention group
Group type: EXPERIMENTAL
Intervention: Amodiaquine (AQ) plus sulfadoxine‐pyrimethamine (SP)
Number of subjects: 2084
Study 16518760 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients infected with parasites containing all 6 mutations of interest
Number of subjects: 2084
Study 12807814 — intervention group
Group type: EXPERIMENTAL
Intervention: Refined quality criteria (80 general criteria and 60 specific criteria)
Number of subjects: 18
Study 12807814 — intervention group
Group type: COMPARATOR
Intervention: Standard review process (without refined criteria)
Number of subjects: 18
Study 11104113 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 11104113 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose alcohol
Number of subjects: 102
Study 11104113 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose alcohol
Number of subjects: 102
Study 9135853 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (negative work, Wneg) at 25% of maximal work capacity
Number of subjects: 12
Study 9135853 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric exercise (negative work, Wneg) at 50% of maximal work capacity
Number of subjects: 12
Study 9135853 — intervention group
Group type: COMPARATOR
Intervention: Concentric exercise (positive work, Wpos) at 50% of maximal work capacity
Number of subjects: 12
Study 7994447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 12.5 mg
Number of subjects: 111
Study 7994447 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 111
Study 7994447 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 3 mg
Number of subjects: 111
Study 7994447 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 6 mg
Number of subjects: 111
Study 7994447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study 2741888 — intervention group
Group type: EXPERIMENTAL
Intervention: High fat meal
Number of subjects: 20
Study 2741888 — intervention group
Group type: COMPARATOR
Intervention: Low fat meal
Number of subjects: 20
Study 2741888 — intervention group
Group type: EXPERIMENTAL
Intervention: GER patients
Number of subjects: 20
Study 5394587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide plus clidinium bromide (Librax(R))
Number of subjects: 42
Study 5394587 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 31780345 — intervention group
Group type: EXPERIMENTAL
Intervention: Voice-hearing
Number of subjects: 95
Study 31780345 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncontrollable thoughts
Number of subjects: 95
Study 31220412 — intervention group
Group type: EXPERIMENTAL
Intervention: Valganciclovir prophylaxis
Number of subjects: 207
Study 31220412 — intervention group
Group type: COMPARATOR
Intervention: Valacyclovir prophylaxis
Number of subjects: 207
Study 31220412 — intervention group
Group type: COMPARATOR
Intervention: Preemptive therapy
Number of subjects: 207
Study 28683833 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-to-skin contact (SSC) for at least one continuous hour daily for 5 weeks
Number of subjects: 116
Study 28683833 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (no SSC)
Number of subjects: 116
Study 24708192 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE-sorafenib
Number of subjects: 91
Study 24708192 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 91
Study 22052893 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 milligrams of atovaquone and 100 milligrams of proguanil (250/100 milligrams) on day -7
Number of subjects: 30
Study 22052893 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 milligrams of atovaquone and 400 milligrams of proguanil (1000/400 milligrams) on day -7
Number of subjects: 30
Study 22052893 — intervention group
Group type: COMPARATOR
Intervention: Placebo (matching placebo for all regimens)
Number of subjects: 30
Study 22052893 — intervention group
Group type: EXPERIMENTAL
Intervention: Atovaquone exposure during liver stage development
Number of subjects: 30
Study 22052893 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak concentration of atovaquone
Number of subjects: 30
Study 22052893 — intervention group
Group type: EXPERIMENTAL
Intervention: Elimination half-life of atovaquone
Number of subjects: 30
Study 22052893 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexposure prophylaxis 4 days after challenge
Number of subjects: 30
Study 20039456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (once daily, starting on postoperative day 1, for up to six consecutive days)
Number of subjects: 90
Study 20039456 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 20039456 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 90
Study 18019590 — intervention group
Group type: EXPERIMENTAL
Intervention: Isokinetic strength measurements (Cybex Norm)
Number of subjects: 44
Study 18019590 — intervention group
Group type: EXPERIMENTAL
Intervention: Wingate anaerobic power test
Number of subjects: 44
Study 18019590 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexibility test, vertical jump test, grip strength test
Number of subjects: 44
Study 18019590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fat-free mass (FFM) control
Number of subjects: 44
Study 18019590 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise linear regression models
Number of subjects: 44
Study 16151830 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity exercise (three 400-kcal sessions per week at 60% of VO(2max))
Number of subjects: 64
Study 16151830 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity exercise (three 400-kcal sessions per week at 80% of VO(2max))
Number of subjects: 64
Study 16151830 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined exercise groups (moderate and high-intensity)
Number of subjects: 64
Study 16151830 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercise)
Number of subjects: 64
Study 11821089 — intervention group
Group type: EXPERIMENTAL
Intervention: Ellios pessaries (2 times 200‐mg pessary/day)
Number of subjects: 123
Study 11821089 — intervention group
Group type: COMPARATOR
Intervention: Utrogestan capsules (2 x 100‐mg capsules, two times a day)
Number of subjects: 123
Study 10064003 — intervention group
Group type: COMPARATOR
Intervention: Lauric acid diet
Number of subjects: 32
Study 10064003 — intervention group
Group type: COMPARATOR
Intervention: Palmitic acid diet
Number of subjects: 32
Study 7654892 — intervention group
Group type: COMPARATOR
Intervention: 5-ASA
Number of subjects: 19
Study 7654892 — intervention group
Group type: COMPARATOR
Intervention: 4-ASA
Number of subjects: 19
Study 2475688 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-release verapamil (SR) 240 mg q.i.d.
Number of subjects: 0
Study 2475688 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release verapamil (IR) 80 mg t.i.d.
Number of subjects: 0
Study 2475688 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release verapamil (IR) 480 mg/day
Number of subjects: 0
Study 22123 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 19
Study 22123 — intervention group
Group type: COMPARATOR
Intervention: H 87/07
Number of subjects: 19
Study 31741279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet animation format of the CHU-9D questionnaire
Number of subjects: 438
Study 31741279 — intervention group
Group type: EXPERIMENTAL
Intervention: Tablet image format of the CHU-9D questionnaire
Number of subjects: 438
Study 31741279 — intervention group
Group type: COMPARATOR
Intervention: Text-based questionnaires
Number of subjects: 438
Study 31741279 — intervention group
Group type: EXPERIMENTAL
Intervention: All formats of the CHU-9D questionnaire
Number of subjects: 438
Study 30536575 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interviewing (BMI)
Number of subjects: 184
Study 30536575 — intervention group
Group type: COMPARATOR
Intervention: Information and Advice (IA)
Number of subjects: 184
Study 30536575 — intervention group
Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 184
Study 30536575 — intervention group
Group type: COMPARATOR
Intervention: IA
Number of subjects: 184
Study 28377393 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention delivered by paediatricians or psychologists (2 consultations covering sleep hygiene and standardized behavioural strategies)
Number of subjects: 320
Study 28377393 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural intervention
Number of subjects: 320
Study 28377393 — intervention group
Group type: COMPARATOR
Intervention: Control group (no sleep training)
Number of subjects: 320
Study 25261702 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin supplementation
Number of subjects: 0
Study 23390994 — intervention group
Group type: EXPERIMENTAL
Intervention: computerized CBT (cCBT)
Number of subjects: 6
Study 23390994 — intervention group
Group type: COMPARATOR
Intervention: therapist-delivered CBT (tCBT)
Number of subjects: 6
Study 22136779 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrous oxide
Number of subjects: 199
Study 22136779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 19193422 — intervention group
Group type: EXPERIMENTAL
Intervention: Finasteride 5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 1)
Number of subjects: 120
Study 19193422 — intervention group
Group type: EXPERIMENTAL
Intervention: Dutasteride 0.5 mg plus alfuzocin 10 mg or tamsulosin 0.2 mg daily (group 2)
Number of subjects: 120
Study 19193422 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of 5ARIs (group 1)
Number of subjects: 120
Study 19193422 — intervention group
Group type: EXPERIMENTAL
Intervention: Withdrawal of 5ARIs (group 2)
Number of subjects: 120
Study 19193422 — intervention group
Group type: EXPERIMENTAL
Intervention: Cessation of 5ARIs (both groups)
Number of subjects: 120
Study 15296472 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical and/or medical therapy for acromegaly
Number of subjects: 16
Study 15296472 — intervention group
Group type: COMPARATOR
Intervention: No therapy (noncontrolled patients)
Number of subjects: 16
Study 15296472 — intervention group
Group type: COMPARATOR
Intervention: Baseline comparison with healthy controls
Number of subjects: 16
Study 11025176 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic catheter (Arrow International, Reading, Pennsylvania, USA)
Number of subjects: 204
Study 11025176 — intervention group
Group type: COMPARATOR
Intervention: Standard triple-lumen polyurethane catheter
Number of subjects: 204
Study 9059403 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (13.5 g I)
Number of subjects: 36
Study 9059403 — intervention group
Group type: COMPARATOR
Intervention: Iopromide (15.0 g I)
Number of subjects: 36
Study 8404100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB), 300 micrograms
Number of subjects: 19
Study 8404100 — intervention group
Group type: COMPARATOR
Intervention: Placebo, 300 micrograms
Number of subjects: 19
Study 8404100 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxitropium bromide (OTB)
Number of subjects: 19
Study 8404100 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 3767008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ranitidine, 150 mg, with 150 ml water
Number of subjects: 140
Study 3767008 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ranitidine, 150 mg, with no further fluid
Number of subjects: 140
Study 3767008 — intervention group
Group type: COMPARATOR
Intervention: Placebo with 150 ml water
Number of subjects: 140
Study 3767008 — intervention group
Group type: COMPARATOR
Intervention: Placebo with no further fluid (BSP only)
Number of subjects: 140
Study 3767008 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine groups
Number of subjects: 140
Study 3767008 — intervention group
Group type: COMPARATOR
Intervention: Placebo groups
Number of subjects: 140
Study 3767008 — intervention group
Group type: COMPARATOR
Intervention: BSP with placebo
Number of subjects: 140
Study 3767008 — intervention group
Group type: COMPARATOR
Intervention: 150 ml water with placebo
Number of subjects: 140
Study 30267481 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Surgicel and histamine‐2 receptor antagonist (H2 RA)
Number of subjects: 157
Study 30267481 — intervention group
Group type: COMPARATOR
Intervention: Monotherapy with a proton pump inhibitor (PPI)
Number of subjects: 157
Study 30267481 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with Surgicel and H2 RA
Number of subjects: 157
Study 27727157 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose maraviroc 300 mg
Number of subjects: 54
Study 24850603 — intervention group
Group type: EXPERIMENTAL
Intervention: α‐lipoic acid (600 mg/day) in addition to basic therapy
Number of subjects: 84
Study 24850603 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy only
Number of subjects: 84
Study 22842339 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF 100/6 μg in pressurised metered-dose inhaler (pMDI) extrafine formulation
Number of subjects: 56
Study 22842339 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol 200 μg pMDI
Number of subjects: 56
Study 22842339 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 56
Study 22842339 — intervention group
Group type: EXPERIMENTAL
Intervention: BDP/FF and Salbutamol
Number of subjects: 56
Study 20047847 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected pregnant women
Number of subjects: 1883
Study 20047847 — intervention group
Group type: COMPARATOR
Intervention: HIV-uninfected pregnant women
Number of subjects: 1883
Study 20047847 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants born to co-infected mothers
Number of subjects: 1883
Study 20047847 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal HCV RNA
Number of subjects: 1883
Study 18779957 — intervention group
Group type: EXPERIMENTAL
Intervention: PSP group
Number of subjects: 7
Study 15761751 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme (ACE) inhibitors
Number of subjects: 735
Study 12718708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing (DB)
Number of subjects: 30
Study 12718708 — intervention group
Group type: EXPERIMENTAL
Intervention: Pursed-Lip Breathing (PLB)
Number of subjects: 30
Study 12718708 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of DB and PLB (CB)
Number of subjects: 30
Study 12718708 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous Breathing (SB)
Number of subjects: 30
Study 10325912 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (budesonide 600 micrograms daily)
Number of subjects: 102
Study 9061129 — intervention group
Group type: EXPERIMENTAL
Intervention: Gericomplex (ginseng, vitamins, minerals and trace elements) - 2 capsules daily for 8 weeks
Number of subjects: 60
Study 9061129 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules - identical in appearance to Gericomplex
Number of subjects: 60
Study 1899204 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide adjustment (PETCO2 between 20 and 80 mmHg)
Number of subjects: 13
Study 1899204 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial Doppler sonography
Number of subjects: 13
Study 6576293 — intervention group
Group type: EXPERIMENTAL
Intervention: Formocresol technique
Number of subjects: 76
Study 6576293 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 76
Study 31343585 — intervention group
Group type: EXPERIMENTAL
Intervention: WCD-guided 6MWT at home
Number of subjects: 197
Study 31343585 — intervention group
Group type: COMPARATOR
Intervention: In-clinic clinician-guided 6MWT
Number of subjects: 197
Study 31343585 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly unsupervised WCD-guided 6MWTs at home
Number of subjects: 197
Study 30499790 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered education and skill-building intervention
Number of subjects: 10
Study 28497756 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (80 mg/m2, 80-120 mg per day, twice daily for 28 days)
Number of subjects: 334
Study 28497756 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study 28497756 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 334
Study 26578538 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 911
Study 26578538 — intervention group
Group type: COMPARATOR
Intervention: Unprotected sex acts
Number of subjects: 911
Study 24439462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal therapy using ranibizumab (n = 11)
Number of subjects: 50
Study 24439462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal therapy using bevacizumab (n = 20)
Number of subjects: 50
Study 24439462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal therapy using triamcinolone (n = 19)
Number of subjects: 50
Study 24439462 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal therapy (all types combined)
Number of subjects: 50
Study 21766975 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered interventions (CDI)
Number of subjects: 225
Study 21766975 — intervention group
Group type: EXPERIMENTAL
Intervention: Booster session
Number of subjects: 225
Study 21766975 — intervention group
Group type: COMPARATOR
Intervention: Brief Motivational Interventions (BMI)
Number of subjects: 225
Study 19178624 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 1 (T1): direct technique with square copings without union in open trays
Number of subjects: 24
Study 19178624 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 2 (T2): square copings splinted with dental floss and autopolymerizing acrylic resin
Number of subjects: 24
Study 19178624 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 3 (T3): square copings splinted with dental floss and autopolymerizing acrylic resin, sectioned and splinted again with autopolymerizing acrylic resin
Number of subjects: 24
Study 19178624 — intervention group
Group type: EXPERIMENTAL
Intervention: Technique 4 (T4): square copings splinted with prefabricated acrylic resin bar
Number of subjects: 24
Study 19178624 — intervention group
Group type: COMPARATOR
Intervention: Control group: metal matrix containing two implants
Number of subjects: 24
Study 17209145 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME‐MD Patient Questionnaire Depression module
Number of subjects: 1632
Study 17209145 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME‐MD Patient Questionnaire Anxiety module
Number of subjects: 1632
Study 17209145 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined PRIME‐MD Patient Questionnaire screen
Number of subjects: 1632
Study 17209145 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall accuracy of PRIME‐MD Patient Questionnaire
Number of subjects: 1632
Study 15547123 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 degrees varus rearfoot wedging
Number of subjects: 30
Study 15547123 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 degrees valgus rearfoot wedging
Number of subjects: 30
Study 15547123 — intervention group
Group type: COMPARATOR
Intervention: rearfoot varus wedging
Number of subjects: 30
Study 11442739 — intervention group
Group type: EXPERIMENTAL
Intervention: Subantimicrobial dose doxycycline (SDD) 20 mg bid
Number of subjects: 0
Study 11442739 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus scaling and root planing (SRP)
Number of subjects: 0
Study 9439561 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfonylurea therapy (gliclazide, ≤ 160 mg.d‐1)
Number of subjects: 227